Paul Sweeney harnesses the power of Bloomberg Intelligence to analyze market news and provide in-depth company and industry research.

AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click ...

Markets are assessing the reshaped US trade landscape after Trump on Thursday laid out steep new tariffs for dozens of ...

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

The Washington Post reported on Friday that state Medicaid programs and Medicare Part D insurance plans will be able to ...

FDA approves Novo Nordisk's Alhemo for hemophilia A and B without inhibitors, following strong Phase 3 results showing reduced bleeding episodes.

Just six weeks ago, things seemed to be getting better for Novo Nordisk A/S. Investors were optimistic, and the Danish drugmaker was briefly Europe’s most valuable public company again. Now, the stock ...

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

Markets are assessing the reshaped US trade landscape after Trump on Thursday laid out steep new tariffs for dozens of ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

The Trump administration is planning a five-year test allowing states to cover weight-loss drugs like Ozempic and Wegovy ...